Eco Animal Health Group PLC New Marketing Authorisations for Aivlosin in China (4879C)
February 23 2022 - 2:00AM
UK Regulatory
TIDMEAH
RNS Number : 4879C
Eco Animal Health Group PLC
23 February 2022
23 February 2022
ECO Animal Health Group plc
("the Company" or the "Group")
(AIM: EAH)
ECO RECIEVES TWO NEW MARKETING AUTHORISATIONS FOR AIVLOSIN(R) IN
CHINA
ECO Animal Health Group plc is pleased to announce that its
subsidiary ECO Animal Health Limited ("ECO") has received two
marketing authorisations from the Ministry of Agriculture and Rural
Affairs ("MOA") of the People's Republic of China for the use of
Aivlosin(R) Water Soluble Granules ("WSG"). Aivlosin(R) is used for
the treatment of a variety of economically important respiratory
and enteric (gut) diseases in pigs and poultry.
The first approval allows ECO to market Aivlosin(R) WSG in China
for the treatment of respiratory disease caused by Mycoplasma and
other sensitive bacteria in chickens laying eggs for human
consumption and breeding chickens. Aivlosin(R) is the first
antimicrobial to be licensed by the Chinese MOA for laying birds
with a zero day drug withdrawal period for eggs.
The second Aivlosin(R) WSG approval is for swine respiratory
disease ("SRD") adding three important bacterial respiratory
pathogens of swine, Haemophilus parasuis, Pasteurella multocida,
and Streptococcus suis to the existing Mycoplasma hyopneumoniae
registration. SRD occurs worldwide and causes major economic losses
to the pig industry due to mortality, reduction in growth rates and
decreased feed efficiency.
Marc Loomes, CEO, commented: "We are delighted to receive these
important marketing authorisations for Aivlosin(R) WSG. China is
the world's largest producer of table eggs and accounts for more
than a third of the world's laying birds. Aivlosin(R) is the first
antimicrobial registered for use in laying hens producing eggs for
human consumption, with a zero day egg withdrawal period. This will
enable ECO to target a new sector, the commercial egg producer,
where Mycoplasmosis can cause significant economic losses. China is
also the largest pork producing country in the world and broader
product label claims in the key SRD segment will serve our business
well as the market recovers in the future."
The information contained within this announcement is deemed by
the Group to constitute inside information as stipulated under the
Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part
of United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via a Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.
Contacts:
ECO Animal Health Group plc
Marc Loomes (CEO)
Christopher Wilks (CFO) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
Singer Capital Markets (Nominated Adviser
& Joint Broker)
Mark Taylor
George Tzimas 020 7496 3000
Peel Hunt LLP (Joint Broker)
James Steel
Dr Christopher Golden 020 7418 8900
Investec (Joint Broker)
Gary Clarence
Alex Penney
Carlo Spingardi 020 7597 5970
Equity Developments
Hannah Crowe
Matt Evans 020 7065 2692
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the Group") researches,
develops and commercialises products for livestock. Our business
strategy is to generate shareholder value by achieving the maximum
sales potential from the existing product portfolio whilst
investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCTTMLTMTTTBFT
(END) Dow Jones Newswires
February 23, 2022 02:00 ET (07:00 GMT)
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Oct 2023 to Oct 2024